Skip NavigationSkip to Content

APOL1 Genotype and Renal Function of Black Living Donors

  1. Author:
    Doshi, Mona D
    Ortigosa-Goggins, Mariella
    Garg, Amit X
    Li, Lihua
    Poggio, Emilio D
    Winkler, Cheryl
    Kopp, Jeffrey B
  2. Author Address

    Division of Nephrology, University of Michigan, Ann Arbor, Michigan; doshimd@med.umich.edu., Division of Nephrology, Miami Transplant Institute, University of Miami, Miami, Florida., Division of Nephrology, Western University, London, Ontario, Canada., Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio; and., Basic Research Laboratory, National Cancer Institute, Leidos Biomedical Research, Frederick Laboratory for Cancer Research, Frederick, Maryland and., Kidney Disease Branch of National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.,
    1. Year: 2018
    2. Date: Apr
    3. Epub Date: 2018 01 16
  1. Journal: Journal of the American Society of Nephrology : JASN
    1. 29
    2. 4
    3. Pages: 1309-1316
  2. Type of Article: Article
  1. Abstract:

    Black living kidney donors are at higher risk of developing kidney disease than white donors. We examined the effect of the APOL1 high-risk genotype on postdonation renal function in black living kidney donors and evaluated whether this genotype alters the association between donation and donor outcome. We grouped 136 black living kidney donors as APOL1 high-risk (two risk alleles; n=19; 14%) or low-risk (one or zero risk alleles; n=117; 86%) genotype. Predonation characteristics were similar between groups, except for lower mean±SD baseline eGFR (CKD-EPI equation) in donors with the APOL1 high-risk genotype (98±17 versus 108±20 ml/min per 1.73 m2; P=0.04). At a median of 12 years after donation, donors with the APOL1 high-risk genotype had lower eGFR (57±18 versus 67±15 ml/min per 1.73 m2; P=0.02) and faster decline in eGFR after adjusting for predonation eGFR (1.19; 95% confidence interval, 0 to 2.3 versus 0.4; 95% confidence interval, 0.1 to 0.7 ml/min per 1.73 m2 per year, P=0.02). Two donors developed ESRD; both carried the APOL1 high-risk genotype. In a subgroup of 115 donors matched to 115 nondonors by APOL1 genotype, we did not find a difference between groups in the rate of eGFR decline (P=0.39) or any statistical interaction by APOL1 status (P=0.92). In conclusion, APOL1 high-risk genotype in black living kidney donors associated with greater decline in postdonation kidney function. Trajectory of renal function was similar between donors and nondonors. The association between APOL1 high-risk genotype and poor renal outcomes in kidney donors requires validation in a larger study. Copyright © 2018 by the American Society of Nephrology.

    See More

External Sources

  1. DOI: 10.1681/ASN.2017060658
  2. PMID: 29339549
  3. PMCID: PMC5875947 [
  4. WOS: 000428896900025
  5. PII : ASN.2017060658

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel